Literature DB >> 23460265

In vivo binding of the dopamine-1 receptor PET tracers [¹¹C]NNC112 and [¹¹C]SCH23390: a comparison study in individuals with schizophrenia.

Eline M P Poels1, Ragy R Girgis, Judy L Thompson, Mark Slifstein, Anissa Abi-Dargham.   

Abstract

RATIONALE: A deficit in dopamine-1 (D1) receptor function in the prefrontal cortex is suggested to play a role in the cognitive dysfunction observed in patients with schizophrenia. However, the results from positron emission tomography imaging studies of D1 receptor levels in individuals with schizophrenia are mixed.
OBJECTIVES: The aim of this investigation was to determine whether the in vivo characteristics of the different D1 receptor tracers used in previous reports, [(11)C]SCH23390 and [(11)C]NNC112, may have contributed to these discrepancies reported in the literature.
METHODS: Eight patients with schizophrenia and 12 healthy control subjects were scanned with both [(11)C]SCH23390 and [(11)C]NNC112.
RESULTS: [(11)C]SCH23390 and [(11)C]NNC112 binding potentials in both patients and control subjects were compared and no tracer by diagnosis interactions were observed.
CONCLUSIONS: The results of this study suggest that differences in the binding of [(11)C]SCH23390 and [(11)C]NNC112 observed in previous studies are not due to differences in the in vivo behavior of these tracers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23460265     DOI: 10.1007/s00213-013-3026-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

Review 1.  D(1) receptors in prefrontal cells and circuits.

Authors:  P S Goldman-Rakic; E C Muly; G V Williams
Journal:  Brain Res Brain Res Rev       Date:  2000-03

Review 2.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

3.  Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain.

Authors:  H Hall; G Sedvall; O Magnusson; J Kopp; C Halldin; L Farde
Journal:  Neuropsychopharmacology       Date:  1994-12       Impact factor: 7.853

Review 4.  Dopamine in schizophrenia: a review and reconceptualization.

Authors:  K L Davis; R S Kahn; G Ko; M Davidson
Journal:  Am J Psychiatry       Date:  1991-11       Impact factor: 18.112

5.  Modulation of memory fields by dopamine D1 receptors in prefrontal cortex.

Authors:  G V Williams; P S Goldman-Rakic
Journal:  Nature       Date:  1995-08-17       Impact factor: 49.962

6.  A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex.

Authors:  M S Lidow; P S Goldman-Rakic
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

7.  Imaging cortical dopamine D1 receptors using [11C]NNC112 and ketanserin blockade of the 5-HT 2A receptors.

Authors:  Ana M Catafau; Graham E Searle; Santiago Bullich; Roger N Gunn; Eugenii A Rabiner; Raul Herance; Joaquim Radua; Magi Farre; Marc Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2009-12-23       Impact factor: 6.200

8.  Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum.

Authors:  O Mawlawi; D Martinez; M Slifstein; A Broft; R Chatterjee; D R Hwang; Y Huang; N Simpson; K Ngo; R Van Heertum; M Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2001-09       Impact factor: 6.200

9.  Expression of serotonin 5-HT(2A) receptors in the human cerebellum and alterations in schizophrenia.

Authors:  S L Eastwood; P W Burnet; R Gittins; K Baker; P J Harrison
Journal:  Synapse       Date:  2001-11       Impact factor: 2.562

10.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

Authors:  Y Okubo; T Suhara; K Suzuki; K Kobayashi; O Inoue; O Terasaki; Y Someya; T Sassa; Y Sudo; E Matsushima; M Iyo; Y Tateno; M Toru
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

View more
  9 in total

1.  Test-retest measurements of dopamine D1-type receptors using simultaneous PET/MRI imaging.

Authors:  Simon Kaller; Michael Rullmann; Marianne Patt; Georg-Alexander Becker; Julia Luthardt; Johanna Girbardt; Philipp M Meyer; Peter Werner; Henryk Barthel; Anke Bresch; Thomas H Fritz; Swen Hesse; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-14       Impact factor: 9.236

2.  Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [¹¹C]NNC112.

Authors:  Judy L Thompson; Daniel R Rosell; Mark Slifstein; Ragy R Girgis; Xiaoyan Xu; Yosefa Ehrlich; Lawrence S Kegeles; Erin A Hazlett; Anissa Abi-Dargham; Larry J Siever
Journal:  Psychopharmacology (Berl)       Date:  2014-04-30       Impact factor: 4.530

Review 3.  Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Authors:  Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2016-03-31       Impact factor: 13.382

4.  Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.

Authors:  Robert A McCutcheon; John H Krystal; Oliver D Howes
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

5.  Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia.

Authors:  Anissa Abi-Dargham; Jonathan A Javitch; Mark Slifstein; Alan Anticevic; Monica E Calkins; Youngsun T Cho; Clara Fonteneau; Roberto Gil; Ragy Girgis; Raquel E Gur; Ruben C Gur; Jack Grinband; Joshua Kantrowitz; Christian Kohler; John Krystal; John Murray; Mohini Ranganathan; Nicole Santamauro; Jared Van Snellenberg; Zailyn Tamayo; Daniel Wolf; David Gray; Jeffrey Lieberman
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 7.348

6.  Dopamine-induced pruning in monocyte-derived-neuronal-like cells (MDNCs) from patients with schizophrenia.

Authors:  Alfredo Bellon; Vincent Feuillet; Alonso Cortez-Resendiz; Faycal Mouaffak; Lan Kong; L Elliot Hong; Lilian De Godoy; Therese M Jay; Anne Hosmalin; Marie-Odile Krebs
Journal:  Mol Psychiatry       Date:  2022-04-01       Impact factor: 13.437

7.  Dopamine in socioecological and evolutionary perspectives: implications for psychiatric disorders.

Authors:  Yoshie Yamaguchi; Young-A Lee; Yukiori Goto
Journal:  Front Neurosci       Date:  2015-06-16       Impact factor: 4.677

8.  [11C]SCH23390 binding to the D1-dopamine receptor in the human brain-a comparison of manual and automated methods for image analysis.

Authors:  Per Stenkrona; Granville J Matheson; Simon Cervenka; Pontus Plavén Sigray; Christer Halldin; Lars Farde
Journal:  EJNMMI Res       Date:  2018-08-02       Impact factor: 3.138

9.  D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients.

Authors:  Per Stenkrona; Granville J Matheson; Christer Halldin; Simon Cervenka; Lars Farde
Journal:  Int J Neuropsychopharmacol       Date:  2019-07-01       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.